Clinical Trial Update: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing PF-05212384 plus irinotecan versus cetuximab plus irinotecan in KRAS/NRAS wild-type metastatic colorectal cancer; study terminated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)
• PF-05212384

Snippet

Sponsor: Pfizer | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-04-27